Central serous chorioretinopathy in uveitis patients after corticosteroid therapy: a report of 6 cases
https://doi.org/10.21516/2072-0076-2021-14-3-65-72
Abstract
Purpose. To report central serous chorioretinopathy (CSCR) in uveitis patients.
Material and methods. A retrospective chart review of uveitis patients seen in a time frame of 20 years at the Centre for Ophthalmic Specialised Care, Lausanne, Switzerland. The ophthalmic and systemic features are presented.
Results. Out of 1793 uveitis patients followed at the Centre for Ophthalmic Specialised Care, 6 patients (0.3%) developed CSСR following corticosteroid therapy due to uveitis. The mean age of patients was 40 ± 13.4 years, disease incidence was not associated with gender. In all 6 patients’ clinical disease was unilateral but subclinical signs were present in all fellow eyes. The mean duration of corticosteroid therapy before CSCR had occurred was 4.95 ± 4.0 months. The mean best-corrected visual acuity at the moment of CSCR was 0.6 ± 0.26 and 0.8 ± 0.17 after discontinuation of corticosteroids. Neurosensory retinal detachment and pigment epithelium detachment were observed in 3 eyes, respectively. During fluorescein angiography (FA), focal dye leakage and areas of alteration of RPE were observed in 6 out of 10 eyes. Diffuse hyperfluorescence of choroidal vessels observed by ICGA was detected in all eyes.
Conclusion. Central serous chorioretinopathy should be suspected when functional and morphological deterioration occurs in uveitis patients receiving corticosteroid therapy with no signs of inflammation reactivation. This complication is extremely rare but serious condition which needs a prompt tapering and discontinuing of corticosteroids.
About the Authors
N. A. Skvortsova
Posterior Eye Segment Diagnostics and Surgery Center;
Inflammatory and Retinal Eye Diseases, Centre for Ophthalmic Specialised
care
Russian Federation
Russian Federation
MD
2 bld., 2, Vladimirskaya str., Moscow, 111123, Russia
Rue Charles-Monnard 6, 1003 Lausanne, Switzerland
I. Papasavvas
Inflammatory and Retinal Eye Diseases, Centre for Ophthalmic Specialised
care
Switzerland
Switzerland
FEBOphth
Rue Charles-Monnard 6, 1003 Lausanne, Switzerland
C. P. Herbort Jr
Inflammatory and Retinal Eye Diseases, Centre for Ophthalmic Specialised
care
Switzerland
Switzerland
MD, PD
Rue Charles-Monnard 6, 1003 Lausanne, Switzerland
References
1. Von Graefe A. Kurzere Abhandlungen. Notizen und casaistische Mitheilungen vermischten Inhalts: VI. Ueber Zentrale Recidivirende Retinitis. Albrecht Von Graefes Arch. Klein. Exp. Ophthalmol. 1866; 12: 211–5.
2. Masuda T. Central serous chorioretinitis. J. Jpn. Ophthalmol. Soc. (Nihon Ganka Gakkai Zasshi) 1917; 21: 777.
3. Spaide R.F., Hall L., Haas A., et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996; 16 (3): 203–13. doi: 10.1097/00006982-199616030-00004
4. Daruich A., Matet A., Dirani A., et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog. Retin. Eye Res. 2015; 48: 82–118. doi: 10.1016/j.preteyeres.2015.05.003.
5. Liu B., Deng T., Zhang J. Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina. 2016; 36 (1): 9–19. doi: 10.1097/IAE.0000000000000837
6. Spitznas M. Pathogenesis of central serous retinopathy: A new working hypothesis. Graefes Arch. Clin. Exp. Ophthalmol. 1986; 224: 321–4. doi: 10.1007/BF02150023
7. Yanagi Y. Pachychoroid disease: a new perspective on exudative maculopathy. Jpn. J. Ophthalmol. 2020; 64: 323–37. doi: 10.1007/s10384-020-00740-5
8. Kuroda S., Ikuno Y., Yasuno Y., et al. Choroidal thickness in central serous chorioretinopathy. Retina. 2013; 33 (2): 302–8. doi: 10.1097/IAE.0b013e318263d11f
9. Chung Y.R., Kim J.W., Kim S.W., et al. Choroidal thickness in patients with central serous chorioretinopathy: assessment of Haller and Sattler layers. Retina. 2016; 36 (9): 1652–7. doi: 10.1097/IAE.0000000000000998
10. Agrawal R., Chhablani J., Tan K.A., et al. Choroidal vascularity index in central serous chorioretinopathy. Retina. 2016; 36 (9): 1646–51. doi: 10.1097/IAE.0000000000001040
11. Yannuzzi L.A., Slakter J.S., Gross N.E., et al. Indocyanine green angiographyguided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003; 23 (3): 288–98. doi: 10.1097/00006982-200306000-00002
12. Lenk J., Sandner D., Schindler L., et al. Hair cortisol concentration in patients with active central serous chorioretinopathy is elevated — a pilot study. Acta Ophthalmol. 2019; 97 (4): e568–e571. doi: 10.1111/aos.13979
13. Chaine G., Haouat M., Menard-Molcard C., et al. Central serous chorioretinopathy and systemic steroid therapy. J. Fr. Ophtalmol. 2001; 24 (2): 139–46.
14. Thinda S., Lam K., Park S.S. Unintentional secondary exogenous corticosteroid exposure and central serous chorioretinopathy. Eye (Lond). 2015; 29 (4): 577–9. doi: 10.1038/eye.2014.328
15. Ricketti P.A., Unkle D.W., Cleri D.J., et al. Central serous chorioretinopathy secondary to corticosteroids in patients with atopic disease. Allergy Asthma Proc. 2015; 36 (2): 123–9. doi: 10.2500/aap.2015.36.3827
16. Ou-Yang P.B., Qi X., Zhu X.H., et al. Central serous chorioretinopathy: signal to reduce corticoid in renal transplant recipients? Transplant Proc. 2015; 47 (7): 2236–8. doi: 10.1016/j.transproceed.2015.07.017
17. Chang Y.S., Weng S.F., Wang J.J., et al. Temporal association between topical ophthalmic corticosteroid and the risk of central serous chorioretinopathy. Int. J. Environ Res. Public Health 2020; 17 (24): 9455. doi: 10.3390/ijerph17249455
18. Nakatsuka A.S., Khanamiri H.N., Lam Q.N., et al. Intranasal corticosteroids and central serous chorioretinopathy: a report and review of the literature. Hawaii J. Med. Public Health. 2019; 78: 151–4.
19. Ge G., Zhang Yu, Zhang Yi, et al. Corticosteroid usage and central serous chorioretinopathy: a meta-analysis. Graefes Arch. Clin. Exp. Ophthalmol. 2020; 258 (1): 71–7. doi: 10.1007/s00417-019-04486-w
20. Abalem M.F., Machado M.C., Veloso Dos Santos H.N., et al. Choroidal and retinal abnormalities by optical coherence tomography in endogenous
21. Cushing’s syndrome. Front Endocrinol (Lausanne) 2016; 7: 154. doi: 10.3389/fendo.2016.00154
22. Ersoz M.G., Hocoaglu M., Muslunas I.S., et al. Development of pachychoroid pigment epitheliopathy and transformation to central serous chorioretinopathy after intravitreal dexamethasone implantation. Retin. Cases Brief Rep. 2018; Sept 26. doi: 10.1097/ICB.0000000000000820
23. Schalenbourg A., Leys A., De Courten C., et al. Corticosteroid-induced central serous chorioretinopathy in patients with ocular inflammatory disorders. Klin. Monbl. Augenheilkd. 2002; 219 (4): 264–7. doi: 10.1055/s-2002-30660
24. Papadia M., Jeannin B., Herbort C.P. Central serous chorioretinopathy misdiagnosed as posterior uveitis and the vicious circle of corticosteroid therapy. J. Ophthalmic Vis. Res. 2015;10 (3): 303–8. doi: 10.4103/2008-322X.170352
25. Khairallah M., Kahloun R., Tugal-Tutkun I. Central serous chorioretinopathy, corticosteroids, and uveitis. Ocul. Immunol. Inflamm. 2012; 20 (2): 76–85. doi: 10.3109/09273948.2011.650776
26. Majumder P.D., Menia N., Sudharshan S., et al. Clinical profiles of uveitis patients developing central serous chorioretinopathy: an experience at a tertiary eye care center in India. Indian J. Ophthalmol. 2019; 67 (2): 247–51. doi: 10.4103/ijo.IJO_831_18
27. Pascual E.V., Mart nez-Costa L., Santander F. Central serous chorioretinopathy and systemic corticosteroids in rheumatic diseases: report of three cases. BMC Musculoskelet Disord. 2015; 16: 378. doi: 10.1186/s12891-015-0843-4
28. Jain I., Singh K. Maculopathy: a corticosteroid side-effect. J. All India Ophthalmol. Soc. 1966; 14: 250–2.
29. Tittl M.K., Spaide R.F., Wong D., et al. Systemic findings associated with central serous chorioretinopathy. Am. J. Ophthalmol. 1999; 128: 63–8. doi: 10.1016/s0002-9394(99)00075-6
30. Haimovici R., Rumelt S., Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110 (4): 698–703. doi: 10.1016/S0161-6420(02)01975-9
31. Tugal-Tutkun I., Herbort C.P. Laser flare photometry, a noninvasive, objective and quantitative method to measure intraocular inflammation. Int. Ophthalmol. 2010; 30 (5): 453–64. doi: 10.1007/s10792-009-9310-2
32. Shin W.B., Kim M.K., Lee C.S., et al. Comparison of the clinical manifestations between acute Vogt-Koyanagi-Harada disease and acute bilateral central serous chorioretinopathy. Korean J. Ophthalmol. 2015; 29 (6): 389–95. doi: 10.3341/kjo.2015.29.6.389
33. Lin D., Chen W., Zhang H., et al. Comparison of the optical coherence tomographic characters between acute Vogt-Koyanagi-Harada disease and acute central serous chorioretinopathy. BMC Ophthalmol. 2014; 28; 14–87. doi: 10.1186/1471-2415-14-87
34. Takayama K., Obata H., Takeuchi M. Efficacy of adalimumab for chronic Vogt-Koyanagi-Harada disease refractory to conventional corticosteroids and immunosuppressive therapy and complicated by central serous chorioretinopathy. Ocul. Immunol. Inflamm. 2020; 28(3): 509–12. doi: 10.1080/09273948.2019.1603312
35. Bousquet E., Zhao M., Daruich A., et al. Mineralocorticoid antagonists in the treatment of central serous chorioretinopathy: review of the preclinical and clinical evidence. Exp. Eye Res. 2019; 187:107754. doi: 10.1016/j. xer.2019.107754
36. van Dijk E.H., Nijhoff M.F., de Jong E.K., et al. Central serous chorioretinopathy in primary hyperaldosteronism. Graefes Arch. Clin. Exp. Ophthalmol. 2016; 254 (10): 2033–42. doi: 10.1007/s00417-016-3417-8
37. Daruich A., Matet A., Dirani A., et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog. Retin. Eye Res. 2015; 48: 82–118. doi: 10.1016/j.preteyeres.2015.05.003
Review
For citations:
Skvortsova N.A., Papasavvas I., Herbort Jr C.P. Central serous chorioretinopathy in uveitis patients after corticosteroid therapy: a report of 6 cases. Russian Ophthalmological Journal. 2021;14(3):65-72. https://doi.org/10.21516/2072-0076-2021-14-3-65-72
Views:
845
Email this article 